利用 BAFF 或 APRIL 分子融合生产多亚型流感病毒样颗粒用于疫苗开发。

Production of Multi-Subtype Influenza Virus-Like Particles by Molecular Fusion with BAFF or APRIL for Vaccine Development.

机构信息

Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.

National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.

出版信息

Methods Mol Biol. 2021;2248:139-153. doi: 10.1007/978-1-0716-1130-2_10.

DOI:10.1007/978-1-0716-1130-2_10

PMID:33185873

Abstract

Virus-like particle (VLP) technology is an alternative platform for developing vaccines to combat seasonal and pandemic influenza. Influenza VLPs are non-infectious nanoparticles that can elicit effective vaccine immunogenicity in hosts. B-cell-activating factor (BAFF, or BLyS) and a proliferation-inducing ligand (APRIL) are members of the tumor necrosis factor (TNF) superfamily of cytokines. Both BAFF and APRIL are homotrimers that interact with homotrimeric receptors. Here, we report a method of the production of influenza VLPs by molecular incorporation with BAFF or APRIL homotrimers to interact with their receptors. We engineered the VLPs by direct fusion of BAFF or APRIL to the transmembrane anchored domain of the hemagglutinin (HA) gene. We also describe procedures for the production of BAFF-VLPs containing H5H7 and H1H5H7 for multi-subtype vaccine development.

摘要

病毒样颗粒（VLP）技术是开发用于防治季节性和大流行性流感疫苗的替代平台。流感 VLP 是无感染性的纳米颗粒，可在宿主中引发有效的疫苗免疫原性。B 细胞激活因子（BAFF，或 BLyS）和增殖诱导配体（APRIL）是肿瘤坏死因子（TNF）细胞因子超家族的成员。BAFF 和 APRIL 都是三聚体，可与三聚体受体相互作用。在这里，我们报告了一种通过分子掺入 BAFF 或 APRIL 三聚体来与它们的受体相互作用生产流感 VLP 的方法。我们通过将 BAFF 或 APRIL 直接融合到血凝素（HA）基因的跨膜锚定域中来设计 VLP。我们还描述了生产包含 H5H7 和 H1H5H7 的 BAFF-VLP 的程序，用于多亚型疫苗的开发。